Lead inhibits secretion of osteonectin/SPARC without significantly altering collagen or Hsp47 production in osteoblast-like ROS 17 2.8 cells

John J. Sauk, Timothy Smith, Ellen K. Silbergeld, Bruce A. Fowler, Martha J. Somerman

Research output: Contribution to journalArticlepeer-review

Abstract

In an effort to better understand the consequences of lead (Pb2+) on skeletal growth, the effects of Pb2+ were investigated using ROS 17 2.8 bone-like cells in vitro. These studies revealed that Pb2+ (4.5 × 10-6 m - 4.5 × 10-7 m) has little or no effect on cell shape except when added immediately following seeding of the cells. However, proliferation of ROS cells was inhibited, in the absence of serum, at concentrations of 4.5 × 10-6 m Pb2+. Protein production was generally increased, however, the major structural protein of bone, type I collagen, production was only slightly altered. Following treatment of ROS cells with Pb2+, intracellular levels of the calcium-binding protein osteonectin/SPARC were increased. Osteonectin/SPARC secretion into the media was delayed or inhibited. Coincident with retention of osteonectin/SPARC there was a decrease in the levels of osteonectin/SPARC mRNA as determined by Northern analysis. These studies suggest that processes associated with osteonectin/SPARC translation and secretion are sensitive to Pb2+.

Original languageEnglish (US)
Pages (from-to)240-247
Number of pages8
JournalToxicology and Applied Pharmacology
Volume116
Issue number2
DOIs
StatePublished - Oct 1992

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint Dive into the research topics of 'Lead inhibits secretion of osteonectin/SPARC without significantly altering collagen or Hsp47 production in osteoblast-like ROS 17 2.8 cells'. Together they form a unique fingerprint.

Cite this